6-K

UNITED STATESSECURITIES AND EXCHANGE COMMISSIONWASHINGTON, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUERPURSUANT TO RULE 13a-16 OR 15d-16 OF THESECURITIES EXCHANGE ACT OF 1934

For the month of February, 2024

Commission File Number: 001-40724

CHINA JO-JO DRUGSTORES, INC.(Translation of registrant’s name into English)

Hai Wai Hai Tongxin Mansion Floor 6 Gong ShuDistrict,

Hangzhou City, Zhejiang Province, People’sRepublic of China, 310008(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F: Form 20-F ☒  Form 40-F ☐

China Jo-Jo Drugstores, Inc., a Cayman Islands exempted company (the “Company”) furnishes under the cover of Form 6-K the following:

1

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

2

Exhibit99.1

ChinaJo-Jo Drugstores, Inc. Announces 1-for-20 Reverse Stock Split

HANGZHOU, China, February 27, 2024 /PRNewswire/ – China Jo-Jo Drugstores, Inc. (the “Company”) (Nasdaq: CJJD), a Cayman Islands exempted company, reported that it expects to implement a 1-for-20 reverse stock split on its ordinary shares (“Ordinary Shares”) effective Friday, March 1, 2024, with trading to begin on a split-adjusted basis at the market open on that day. Trading in the Ordinary Shares will continue on the Nasdaq Capital Market under the symbol “CJJD”. The new CUSIP number for the Ordinary Shares following the reverse stock split is G2124G 120.

Upon the effectiveness of the reverse stock split, every 20 shares of the Company’s issued and outstanding Ordinary Shares, par value $0.012 per share, will automatically be converted into one issued and outstanding Ordinary Share, par value $0.24 per share. No fractional shares will be issued as a result of the reverse stock split. Instead, any fractional shares that would have resulted from the split will be rounded up to the next whole number. The reverse stock split affects all shareholders uniformly and will not alter any shareholder’s percentage interest in the Company’s outstanding Ordinary Shares, except for adjustments that may result from the treatment of fractional shares.

The reverse stock split at a ratio of 1-for-20 shares was approved by the Company’s board of directors and its shareholders. The Company is to file a Third Amended and Restated Memorandum and Articles of Association with the Cayman Islands Registrar of Companies effective March 1, 2024.

AboutChina Jo-Jo Drugstores, Inc.

China Jo-Jo Drugstores, Inc. ("Jo-Jo Drugstores" or the "Company"), is a leading online and offline retailer and wholesale distributor of pharmaceutical and other healthcare products and a provider of healthcare services in China. Jo-Jo Drugstores currently operates an online pharmacy and retail drugstores with licensed doctors on site for consultation, examination and treatment of common ailments at scheduled hours. It is also a wholesale distributor of products similar to those carried in its pharmacies. For more information about the Company, please visit http://jiuzhou360.com. The Company routinely posts important information on its website.

Forward-LookingStatements

Thispress release contains information about the Company's view of its future expectations, plans and prospects that constitute forward-lookingstatements. Actual results may differ materially from historical results or those indicated by these forward-looking statements as aresult of a variety of factors including, but not limited to, risks and uncertainties associated with its ability to raise additionalfunding, its ability to maintain and grow its business, variability of operating results, its ability to maintain and enhance its brand,its development and introduction of new products and services, the successful integration of acquired companies, technologies and assetsinto its portfolio of products and services, marketing and other business development initiatives, competition in the industry, generalgovernment regulation, economic conditions, dependence on key personnel, the ability to attract, hire and retain personnel who possessthe technical skills and experience necessary to meet the requirements of its clients, and its ability to protect its intellectual property.The Company's encourages you to review other factors that may affect its future results in the Company's annual reports and in its otherfilings with the Securities and Exchange Commission.

For moreinformation, please contact:

CompanyContact:

Frank Zhao

Chief Financial Officer

+86-571-88077108

[email protected]

InvestorRelations Contact:

Tina Xiao

Ascent Investor Relations LLC

+1- 646-932-7242

[email protected]